Managing HIV lipoatrophy.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000188:drug therapy; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000077154:Rosiglitazone; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D019382:Human Growth Hormone; D007004:Hypoglycemic Agents; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D000077154:Rosiglitazone; D018119:Stavudine; D045162:Thiazolidinediones; D000099227:Abacavir